Biomarker Testing and NSCLC, Part 1

Today we are joined by Dr. Rajat Thawani. He discusses why biomarker testing is crucial in guiding treatment decisions for patients with ROS1 mutations in NSCLC. He also highlights how specialized biomarker testing teams enhance the identification and management of patients with ROS1-positive NSCLC by providing knowledge about resistance mechanisms and helping select appropriate therapies.

Let us know what you thought of this week’s episode on Twitter: @physicianswkly

Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!

Thanks for listening!